Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Medicine Faculty Publications

Medicine

2014

Development and validation of an algorithm to
identify patients newly diagnosed with HIV
infection from electronic health records
Matthew B. Goetz
University of California, Los Angeles

Tuyen Hoang
University of California, Los Angeles

Virginia Kan
George Washington University

David Rimland
Emory University

Maria Rodriguez-Barradas
Baylor College of Medicine

Follow this and additional works at: https://hsrc.himmelfarb.gwu.edu/smhs_medicine_facpubs
Part of the Medicine and Health Sciences Commons
Recommended Citation
Goetz, M.B., Hoang, T., Kan, V.L., Rimland, D., Rodriguez-Barradas, M. (2014). Development and validation of an algorithm to
identify patients newly diagnosed with HIV infection from electronic health records. AIDS Research and Human Retroviruses, 30(7),
626-633.

This Journal Article is brought to you for free and open access by the Medicine at Health Sciences Research Commons. It has been accepted for
inclusion in Medicine Faculty Publications by an authorized administrator of Health Sciences Research Commons. For more information, please
contact hsrc@gwu.edu.

AIDS RESEARCH AND HUMAN RETROVIRUSES
Volume 30, Number 7, 2014
ª Mary Ann Liebert, Inc.
DOI: 10.1089/aid.2013.0287

EPIDEMIOLOGY

Development and Validation of an Algorithm to Identify
Patients Newly Diagnosed with HIV Infection from
Electronic Health Records
Matthew Bidwell Goetz,1 Tuyen Hoang,1 Virginia L. Kan,2 David Rimland,3 and Maria Rodriguez-Barradas 4

Abstract

An algorithm was developed that identifies patients with new diagnoses of HIV infection by the use of
electronic health records. It was based on the sequence of HIV diagnostic tests, entry of ICD-9-CM diagnostic
codes, and measurement of HIV-1 plasma RNA levels in persons undergoing HIV testing from 2006 to 2012 at
four large urban Veterans Health Administration (VHA) facilities. Source data were obtained from the VHA
National Corporate Data Warehouse. Chart review was done by a single trained abstractor to validate site-level
data regarding new diagnoses. We identified 1,153 patients as having a positive HIV diagnostic test within the
VHA. Of these, 57% were determined to have prior knowledge of their HIV status from testing at non-VHA
facilities. An algorithm based on the sequence and results of available laboratory tests and ICD-9-CM entries
identified new HIV diagnoses with a sensitivity of 83%, specificity of 86%, positive predictive value of 85%,
and negative predictive value of 90%. There were no meaningful demographic or clinical differences between
newly diagnosed patients who were correctly or incorrectly classified by the algorithm. We have validated a
method to identify cases of new diagnosis of HIV infection in large administrative datasets. This method, which
has a sensitivity of 83%, specificity of 86%, positive predictive value of 85%, and negative predictive value of
90% can be used in analyses of the epidemiology of newly diagnosed HIV infection.

Introduction

A

pproximately 18% of the 1.1 million HIV-infected
persons in the United States do not know their status and
therefore cannot benefit from life-saving and restoring
treatment.1 This gap has led the Veterans Health Administration (VHA), Centers for Disease Control and Prevention
(CDC), American College of Physicians (ACP), and U.S.
Preventive Services Task Force to recommend that routine,
voluntary HIV testing be offered to adults.2–5
The VHA has committed substantial resources to promote
HIV testing.6–8 These efforts have borne fruit.6,9,10 However,
it is not known whether the ultimate goal of expanded HIV
testing has been achieved, namely, to what degree does expanded HIV testing identify patients with previously unknown HIV infection and, even more crucially, whether
newly diagnosed patients are being promptly linked to appropriate medical care. Timely care linkage is associated
with meaningful improvements in clinical outcomes11–14 but

does not occur in approximately 25% of newly diagnosed
HIV-infected patients in the United States.1,15,16 Variations
in linkage help to explain gender and racial/ethnic disparities
in HIV treatment outcomes.13,14,17 The importance of linkage
has prompted the National HIV/AIDS Strategy (NHAS) to
call for action to ensure that 85% of newly diagnosed patients
are linked to care within 3 months of diagnosis.18
Both assessment of linkage to care for newly diagnosed
patients and evaluation of the efficiency of routine HIV
testing require the ability to discriminate between newly diagnosed patients and patients with previously known HIV
infection who undergo repeated testing upon transfer of care
from one healthcare system to another or for other reasons.
This distinction is critical as previously diagnosed patients
are often actively seeking care and thus may be more motivated to engage in care than are newly diagnosed patients.
The ability to identify newly diagnosed HIV-infected patients in large cohorts would enable analyses of variances in
diagnostic rates of previously undetected HIV infection, as
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well as permit evaluation of subsequent progression through
the continuum of care. However, there is no validated procedure for using data from medical records to identify newly
diagnosed HIV-infected patients within large observational
cohorts. To address this deficit, we determined the ability of
using the sequential timing of laboratory results and diagnostic codes to identify newly diagnosed cases as recorded in
electronic health records (EHR) of HIV infection among
persons receiving care within the VHA.
Materials and Methods

The cohort of this study included all patients seen at four
large urban VHA facilities in Los Angeles, Houston, Washington, D.C., and Atlanta who had positive HIV antibody
tests from August 2006 to August 2012. This time period was
selected to obtain a representative sample of patients undergoing HIV testing before and after implementation of routine
HIV testing in VHA in August 2009; previous to that time
VHA policy recommended risk-based HIV testing.
We obtained data spanning the period from 2000 to 2012
from the VHA National Corporate Data Warehouse that included patient visits, demographics, laboratory test results,
International Classification of Diseases, Ninth Revision and
Clinical Modification (ICD-9-CM) diagnostic codes, and
factors used by a risk-based prompt for HIV testing used by
some VHA facilities.6 In addition, we obtained direct access
to facility-level EHR of the cohort of patients with confirmed
positive HIV tests from the four study sites.
We distinguished newly diagnosed patients from patients
who were previously diagnosed with HIV infection and who
underwent repeat or confirmatory HIV testing by assessing
the temporal relationship of the ordering of HIV antibody
tests and plasma HIV-1 RNA measurement, and the recording of ICD-9-CM codes for HIV infection. We reasoned that
for persons with no prior evidence of HIV infection (i.e.,
newly diagnosed patients) measurement of HIV-1 plasma
RNA levels and recording of HIV-specific ICD-9-CM diagnoses would occur after the performance of HIV antibody
testing, whereas for persons already known to be HIV infected, plasma HIV-1 RNA testing and ICD-9-CM code entry
would be recorded either before or at the same time as HIV
antibody testing was performed. Finally, we reasoned that
persons with undetectable or low levels of plasma HIV-1
RNA were likely to be receiving antiretroviral therapy and
thus were previously diagnosed.
Based on the aforementioned principles, the following
sequential procedures were used to classify patients based on
HIV-1 antibody tests, Western blot tests, HIV-1 plasma RNA
levels, and ICD-9-CM codes contained within EHR data
available in the VA Corporate Data Warehouse. Further details are provided in Fig. 1 and the Appendix.
Stage 1: Identify patients with a nonnegative HIV antibody
test from August 2006 to August 2012. Nonnegative HIV
antibody tests included instances in which the result was
recorded as ‘‘positive,’’ ‘‘reactive,’’ ‘‘comment,’’ or similar
language that did not identify the test as being negative.
Stage 2: Exclude from all instances patients for whom a
prior HIV antibody test was positive.
Stage 3: Identify patients with confirmed HIV infection.
Confirmation of HIV infection required a positive antibody
test plus either a diagnostic HIV Western blot or quantifiable
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HIV-1 RNA in plasma. Plasma HIV-1 RNA values were
sought only in persons in whom Western blot test results were
unavailable, or the result was recorded as ‘‘indeterminate’’ or
‘‘comment’’ or similar language was used. For such persons,
if the HIV-1 plasma RNA level was recorded as being below
the lower limit of quantification or results were not available,
the patient was categorized as having ‘‘unconfirmed HIV
status.’’ Persons with negative Western blots were considered
to be uninfected and were excluded from further analyses.
Stage 4: Determine whether patients with confirmed HIV
infection were newly diagnosed or had previously been
identified as being HIV infected. Patients who underwent
standard blood-based HIV-1 testing were considered as
having been previously known to be HIV infected if the date
of the first HIV-1 plasma RNA determination or ICD-9-CM
record of HIV diagnosis was on or before the date the HIV
antibody test was ordered, or if the first HIV-1 plasma RNA
level was below the lower limit of quantification. Patients in
whom there was neither an HIV-1 plasma RNA determination nor an entry of an HIV-related ICD-9-CM code were
considered to be unclassifiable.
We made an exception for persons undergoing HIV Point
of Care (i.e., Rapid) testing, wherein clinicians had rapid
access to preliminary positive HIV test results and therefore
often ordered HIV-1 plasma RNA tests and recorded the
appropriate ICD-9-CM code on the same date as the Point of
Care test was ordered. Consequently, patients who underwent
HIV-1 Point of Care testing were considered to have been
previously known to be HIV infected only if the date of the
first HIV-1 plasma RNA determination or ICD-9-CM record
of HIV diagnosis was before the date the HIV antibody test
was ordered.
Site investigators reviewed the medical records and other
locally available information for each patient at their facility
with a positive HIV antibody test to determine whether each
positive test represented a new diagnosis of HIV infection or
confirmation of a previously established infection. To confirm that these classifications were correct, a single trained
abstractor used the VA Compensation and Pension Record
Interchange (CAPRI) system to review the EHR of all patients identified as having newly diagnosed HIV infection. In
addition, records of patients identified as having previously
diagnosed HIV infection at each site were rereviewed. A
prior diagnosis of HIV infection was confirmed in 287 of 289
patients at the first two sites evaluated. Based on this experience a limited, random sampling of 30 patients determined
to have been previously diagnosed by each of the other two
local site investigators was rereviewed; all 60 of these patients were confirmed as having had a previous diagnoses of
HIV infection. A senior investigator rereviewed all charts in
which there was disagreement between the assignment made
by the local investigator and the chart abstractor and made a
final determination as to whether the HIV test result represented a newly made diagnosis. This final adjudicated
chart review served as the reference standard in assessments
of the validity of the algorithm.
The statistical methods include frequencies to summarize
the distributions of demographic and clinical characteristics
of the patients across four study sites (see Table 1). Measures
to validate the algorithm include sensitivity, which is the
proportion of patients classified as new diagnoses by the algorithm among the new diagnoses based on chart review;
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FIG. 1. Characterization and
distribution of patients with
nonnegative HIV antibody
tests. Nonnegative HIV antibody tests included instances
in which the result was recorded as ‘‘positive,’’ ‘‘reactive,’’ ‘‘comment,’’ or a
similar text. Of the 672
western blot results that
were neither negative nor
positive, the western blot
result was reported as
‘‘comment’’ in 606 cases and
as ‘‘I’’ in 8 cases; in 58 cases
no western blot result was
found. HIV-1 RNA was detected in three of five tests
performed when the western
blot was reported as ‘‘comment,’’ in one of the seven
tests performed when the
western blot was reported as
‘‘I,’’ and in 36 of the 47 tests
performed when no western
blot result was found.
*LLQ = lower limit of quantification. **If HIV rapid
testing was done, patients
were classified as having a
prior non-VA diagnosis if the
first viral load or ICD-9-CM
entry is before the date that
the rapid test was ordered.

specificity, which is the proportion of patients classified as
non-VHA diagnoses by the algorithm among the non-VHA
diagnoses based on chart review; positive predictive value,
which is the proportion of new diagnoses based on chart review among the new diagnoses classified by the algorithm; and
negative predictive value, which is the proportion of non-VHA
diagnoses based on chart review among the non-VHA diagnoses classified by the algorithm (see Tables 2 and 4). Finally,
frequencies and chi-square tests were used to compare demographics, clinical characteristics, and care utilization between correctly classified and misclassified diagnoses (see
Table 3). The study protocol was approved by the VA Central
Institutional Review Board and by the Research and Development Committees at each of the participating facilities.
Results

Each site contributed 239 to 386 unique patients with
positive HIV antibody tests to the study cohort. Five patients
from Site 2 and one patient from Site 4 were missing from the
VA National Corporate Data Warehouse; therefore a total of
1,147 patients comprised the final analytical cohort available

for algorithm validation analysis (Table 1). As per the adjudicated chart review, the first positive HIV antibody test represented a new diagnosis 43% of the time; this varied from
30% to 64% across the sites. While gender and age distributions were similar across the sites ( > 95% male, mean
age = 52 years), race and ethnicity varied with African
Americans constituting from 52% to 82% of new diagnoses.
The correlation between local site designation and central
chart review of patients as having new HIV diagnoses ranged
from 87% (Site 3) to 100% (Site 1); data not shown.
Table 2 provides the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of
the algorithm. Overall, the algorithm achieved a sensitivity of
83%, specificity of 86%, positive predictive value of 85%,
and negative predictive value of 90%. The most frequent
contributors to decreased sensitivity of the algorithm were
instances in which patients underwent standard blood-based
HIV antibody testing and had a measurement of HIV-1
plasma RNA levels done the same day. Revision of the algorithm to classify such patients as being newly diagnosed
increased the sensitivity of the algorithm to 89% but reduced
the specificity to 58%. Chart review indicated that the most
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Table 1. Demographic and Clinical Characteristics of Study Patients
Characteristics
Adjudicated HIV status
New diagnoses
Known diagnoses
Gender (%)
Female
Male
Age
Mean (SD)
Race/ethnicity (%)
White
African American
Others
Marital status (%)
Single
Married
Other
Risk factors (%)a
Hepatitis B infection
Hepatitis C infection
Prior STD
Drug use
Homelessness
Any risk factors
Point of care diagnosis (%)

Site 1 n = 239

Site 2 n = 381

Site 3 n = 228

Site 4 n = 299

Total N = 1,147

74 (31%)
165 (69%)

115 (30%)
266 (70%)

112 (49%)
116 (51%)

190 (64%)
109 (36%)

491 (43%)
655 (57%)

3
97
52 (12)

4
96

2
98

52 (12)

5
95

53 (12)

51 (12)

4
96
52 (12)

36
52
12

34
60
6

8
82
10

13
77
10

23
68
9

58
8
34

41
13
46

47
14
39

40
14
46

46
13
42

11
24
15
32
42
64
2.5

8
22
20
31
23
59
5.0

6
33
21
35
35
69
16.2

6
16
22
32
24
61
0.7

7
22
20
32
30
62
5.6

a

These factors have been used as a prompt to offer HIV testing to patients receiving care.6
STD, sexually transmitted disease.

common circumstance leading to categorization of a previously diagnosed patient as being newly diagnosed was due
to the provider not being aware that the patient had a previous diagnostic test at a non-VHA facility and therefore not
recording a diagnostic code for HIV infection or ordering
HIV-1 RNA levels when antibody testing was done. Evidence concerning these prior HIV diagnoses was found in
chart notes that were often written well after the date of the
HIV testing. Thirty-seven other patients could not be classified by the algorithm; these included cases with a positive
HIV antibody test and Western blot but no plasma HIV-1
RNA test or ICD-9-CM code (unclassifiable, n = 20), cases
with positive HIV antibody tests but no identifiable confirmatory Western blot or plasma HIV-1 RNA (unconfirmed
status, n = 12), and cases without records of positive antibody tests in the VA Corporate Data Warehouse (n = 5). We
found that these misclassified cases were more likely than
classified cases to not have any visits to the VA in the year
after HIV diagnostic testing was performed, and had fewer
documented HIV-associated risk factors (49% versus 59–
65%) or mental health conditions (43% versus 53–65%;
Table 3).

To ascertain whether the algorithm mischaracterized patients at random or whether particular groups of patients were
liable to be misclassified, we compared the patient-level
demographics, clinical characteristics, and frequency of care
utilization between the 409 correctly classified and 60 misclassified new diagnoses, and also the 566 correctly classified
and 75 misclassified non-VA diagnoses. Pairwise comparison showed no meaningful differences between the 409
persons correctly classified as being newly diagnosed with
HIV infection and the 60 newly diagnosed patients who were
misclassified as having a previously known HIV diagnoses.
However, due to the disproportionate use of HIV rapid testing
by one site (Site 3), we found that the 75 previously diagnosed persons who were misclassified as being new diagnoses were more likely to be African American than were the
566 persons correctly classified as having been previously
diagnosed with HIV infection (72% vs. 58%).
We conducted several sensitivity analyses. First, we examined how plasma HIV-1 RNA thresholds or elimination of
virological criteria affected the performance of the algorithm
(Table 4). We found that the predictive power of the algorithm was optimal when the virological threshold was set as

Table 2. Performance Characteristics of the Algorithm in the Identification of Newly Diagnosed Patients
Sites

N

New diagnosis

Prior non-VA diagnosis

Sensitivity

Specificity

PPV

NPV

Site 1
Site 2
Site 3
Site 4
Total

239
386
228
300
1153

74
115
112
190
491

165
271
116
110
662

86%
79%
77%
88%
83%

88%
89%
81%
79%
86%

81%
81%
83%
89%
85%

95%
93%
84%
84%
90%

VA, Veterans Administration; PPV, positive predictive value; NPV, negative predictive value.
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Table 3. Factors Associated with Misclassifications of HIV Diagnoses by the Algorithm
Adjudicated status
New diagnosis
New diagnosis
Prior diagnosis
Prior diagnosis
Other
Correct (N = 409) Incorrect (N = 60) Correct (N = 566) Incorrect (N = 75) None (N = 37)
Patient-level variations
Gender (%)
Female
Male
Age
Mean (SD)
Race/ethnicity (%)
White
African American
Others
Marital status (%)
Single
Married
Other
Risk factors (%)
HepB
HepC
STD
Drug use
Homeless
All risk factors
Mental health (%)
Care utilization before dx (%)
No visit in year before dx
1 visit
2 + visits
Care utilization after dx (%)
No visit in year after dx
1 visit
2 + visits
Provider-level variation
% HIV Ab tests ordered by
Attending physician
Trainee
Mid-level provider
Others/missing
Clinic-level variation
Location of HIV testing (%)
Primary care clinic
Infectious disease clinic
Other clinics

5
95

3
97

3
97

1
99

0
100

53 (12)

51 (12)

52 (12)

50 (12)

48 (13)

14
77
9

20
77
3

32
58a
10

19
72a
9

30
54
16

39
14
47

38
15
47

50
11
39

47
19
34

51
11
38

8
23
24
35
32
69
61

8
22
25
35
30
65
65

8
23
18
31
28
59
58

5
23
15
35
32
60
53

0
16
8
24
24
49b
43b

8
12
80

17
5
78

22
21
57

16
24
60

19
24
57

1
0
99

0
2
98

2
3
95

0*
3
97

19b
30
51

56
17
21
6

55
20
15
10

40
7
45
8

49
9
35
7

47
3
36
14b

51
2
47

58
2
40

37
18
45

44
2
54

50
6
44

a

Comparisons between indicated groups are statistically significant at p-values < 0.05.
Comparisons between indicated group and all other groups are statistically significant at p-values < 0.05.
HepB, hepatitis B; HepC, hepatitis C; STD, sexually transmitted disease; dx, diagnosis; Ab, antibody.
b

less than the lowest quantifiable plasma HIV-1 RNA value as
determined by the locally used laboratory assay or when virological criteria were not used to discriminate between new
and previously diagnosed patients with sensitivity and positive
predictive values of 83% and 86%, and 84% and 85%, respectively. On the first test that was done, 5.1% of the 491 new
diagnoses by chart review had unquantifiable plasma HIV-1
RNA (i.e., had a value below the limits of detection of the
assay that was used). We next evaluated whether the initial
CD4 + lymphocyte count discriminated between new and
previously diagnosed patients. For newly diagnosed patients
the median initial CD4 + lymphocyte count was 73 cells/ll
[interquartile range (IQR) 20–382] whereas for previously
diagnosed patients the median was 326 (IQR 90–565). As

shown in Table 4, addition of CD4 + cell criteria to the base
case virological criteria substantially reduced the sensitivity of
the algorithm. Finally, as CD4 cell counts were generally
performed at the same times as viral load measurements, these
values provided no independent information.
Discussion

We developed an algorithm using electronic health records
to differentiate between persons with newly diagnosed HIV
infection and those with previously established infection who
underwent repeated testing. This algorithm correctly identified newly diagnosed patients with 83% sensitivity and an
85% positive predictive value. In contrast, only 43% (491) of
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Table 4. Effects of Varying Thresholds for Initial Plasma HIV-1 RNA Values or Addition of CD4 +
Lymphocyte Counts on the Performance Characteristics of the Diagnostic Algorithm

Thresholds for undetected plasma HIV-1 RNA
No threshold used
Less than the lower level of quantification
Less than 200 copies/ml
Less than 500 copies/ml
Less than 1,000 copies/ml
Less than 5,000 copies/ml
Less than 10,000 copies/ml
Thresholds for CD4 + cell count
CD4 + count > 200 cells/ll
CD4 + count > 500 cells/ll

Sensitivity (%)

Specificity (%)

PPV (%)

NPV (%)

84%
83%
73%
71%
69%
56%
50%

85%
86%
88%
89%
89%
90%
91%

82%
85%
85%
85%
86%
85%
87%

90%
90%
81%
80%
80%
74%
72%

33%
16%

92%
94%

82%
81%

66%
62%

Change in the sensitivity and specificity of the algorithm if CD4 + lymphocyte criteria are added to the base condition (wherein patients
were considered to have prior diagnoses of HIV infection if there was any detectable viral load). Patients under the virological criteria or
over the CD4 + cell count were considered to have prior diagnoses.

the 1,153 positive HIV antibody tests in these four VHA
facilities represented a new diagnosis of HIV infection; the
remaining positive tests were performed in persons who were
already aware of their HIV status.
The algorithm was based on the sequential timing of HIV
antibody tests, measurements of HIV-1 plasma RNA levels,
and recording of diagnostic codes. In clinical practice HIV-1
plasma RNA levels are rarely performed for persons whose
HIV status is not known; exceptions are generally limited to
persons with acute HIV seroconversion syndromes or to
persons in clinical circumstances in which HIV infection is
highly likely (e.g., acute opportunistic infection). However,
in sensitivity analyses we found that use of HIV-1 plasma
RNA values did not improve the ability of the algorithm to
distinguish between prior and new HIV diagnoses. In addition, we found that the value of timing or value of CD4 +
lymphocyte counts did not improve the accuracy of the
algorithm.
We identified two issues that were the main contributors to
the decreased accuracy of the algorithm. The first issue involved HIV Point of Care testing. Because results of Point of
Care tests could be read within 20 min after performance,
providers often ordered measurements of plasma HIV-1
RNA on the same date as a positive Point of Care test was
reported. As information in the laboratory results database
did not consistently specify that HIV-1 Point of Care testing
had been performed, patients undergoing HIV rapid testing
were often misidentified as having undergone standard
blood-based antibody testing. Consequently, when HIV-1
plasma RNA levels were determined on the same day, the
algorithm incorrectly classified them as having previously
established diagnoses of HIV infection. The second issue
involved patients who were diagnosed prior to entering VHA
care and who did not disclose their HIV status until after they
underwent repeat HIV testing. For these patients, VHA providers ordered plasma HIV-1 RNA measurements after their
positive antibody tests were confirmed; consequently, the
algorithm incorrectly classified them as new diagnoses. This
misclassification reduced the specificity of the algorithm
from 97% to 86%.
The strengths of the algorithm validation are that it relied
upon a rigorous adjudication process to identify newly

diagnosed patients and that the validation was done using
patients from four geographically diverse sites with differing
demographics, clinical characteristics, HIV testing methodologies, recording of laboratory information, and frequency
of new diagnoses. The consistency of performance of the
algorithm in the face of such diversity strengthens confidence
in the use of this tool to identify new diagnoses in other
settings. In addition, no differences were found in the characteristics of patients who were properly or improperly
classified as new HIV diagnoses.
Limitations of our work include the fact that our results
may not be generalizable outside of a VHA setting, particularly as very few women were included in our cohort, and will
not be feasible for cohorts that do not record ICD-9-CM
codes or laboratory results as directly analyzable fields in
EHR. Alternative methods to distinguish between persons
with positive HIV antibody tests that represent a newly diagnosed infection and confirmation of a previously established diagnosis will need to be developed for these cohorts.
In addition, we were hampered by an inability to consistently
distinguish between standard blood-based HIV testing and
Point of Care testing. This misclassification, which had a
major affect on assay performance as 81% of patients diagnosed on the basis of a positive Point of Care test had a
plasma HIV-1 RNA assay on the same day as the Point of
Care test, could have been resolved if key words such as
‘‘ rapid’’ or ‘‘point of care’’ were explicitly indicated in the
laboratory test names. Alternatively, accurate and reliable
time stamps that included the time of day as well as the date
of test performance or natural language processing of text
notes could be used to determine whether orders for virologic
tests were concurrent with or followed Point of Care diagnostic tests.
The other major source of misclassification was due to the
reliance solely on administrative and laboratory data and the
exclusion of information contained in narrative notes. While
natural language processing methods could be used to extract
narrative data and overcome this limitation, there are many
challenges due to the unstructured nature of how and when
information regarding the timing of HIV infection is recorded. Finally, the algorithm does not identify newly diagnosed persons who present with acute HIV infection and lack
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detectable antibody or who are elite controllers with low or
undetectable HIV-1 plasma RNA levels.
This work has clinical implications for future epidemiologic research regarding the frequency and epidemiology of
new diagnoses of HIV infection and for evaluation of the
patterns and outcomes of care in such individuals. A validated method to identify cases of new diagnosis of HIV infection will enable a more thorough delineation of the
frequency of newly diagnosed HIV infection in differing
communities and demographic settings and thus inform the
development of programs to increase the efficiency and
utility of efforts to promote HIV testing among the most
vulnerable patients. In this regard the CDC has recommended
that 80% of expanded HIV testing efforts should be focused
on sites with a ‡ 2% rate of positive HIV tests.19 Furthermore, identification of the newly diagnosed patients will
allow for detailed analyses of the effectiveness of programs
to ensure that these patients are linked to care in a timely
manner. At present, timely care linkage occurs in less than
65% of newly diagnosed HIV-infected patients in the United
States.15 Variations in linkage to care are likely to explain
much of the gender and racial/ethnic disparities in HIV
treatment outcomes13,14,17 and underscore the importance of
the NHAS goal to ensure that 85% of newly diagnosed patients are linked to care within 3 months of diagnosis.18
As recommended by the CDC,19 additional efforts should
be taken to ensure that the highest risk patients are being
tested for HIV infection. Both the need to develop such
programs and the design of such an intervention require
knowledge of the distribution of newly diagnosed HIVinfected patients and thus a systematic approach to detect
such patients. The algorithm we have developed provides
means to acquire this information. Such a tool is also needed
to assess geographic-, institutional-, and patient-level variations in linkage to medical care of newly diagnosed HIVinfected patients; such data will inform the development of
interventions to reduce such variations, improve overall
linkage, and assist the medical care system in meeting NHAS
goals.18,20,21
Appendix

To accurately distinguish newly diagnosed patients from
non-VA diagnosed patients, we paid careful attention to data
cleaning of laboratory tests and ICD-9-CM codes. Unlike ICD9-CM codes, which are standardized data, laboratory tests are
free-text data entered by local laboratory staff, leading to increased data entry errors such as misspelling, obscure abbreviations, and obscure test results. In addition, some ordered
tests were cancelled and some test results were not reported or
were reported in delayed time. To resolve these problems, we
cleaned the data as follows.
 ICD-9-CM codes: We used the following ICD-9-CM
codes: AIDS (042), asymptomatic HIV (V08), and
HIV-related codes (042.0-.2, 042.9, 043.0-.3, 043.9,
044.9, 079.53).
 Laboratory names: We used key words such as ‘‘HIV’’
and ‘‘immunodeficient’’ to search for HIV tests in general. Then we printed out the test names and had an HIV
specialist review these test names and classify them into
Antibody tests, Western blot confirmatory tests, and
Plasma HIV-1 RNA tests. Then we wrote programming

GOETZ ET AL.

codes to classify these tests based on their names. For
example, Antibody test names contained key words such
as ‘‘antibody,’’ ‘‘AB,’’ ‘‘Rapid HIV,’’ ‘‘point of contact,’’ and ‘‘needle stick’’; Western blot test names
contained key words such as ‘‘Western blot,’’ ‘‘WB,’’
‘‘reflex,’’ and ‘‘confirm’’; while Plasma HIV-1 RNA test
names contained key words such as ‘‘Plasma HIV-1
RNA,’’ ‘‘PCR,’’ ‘‘RNA,’’ and ‘‘quant.’’ Of note, we
found Western blot test names without key words
‘‘HIV.’’ For example, one facility named its Western blot
test as ‘‘WB int’’ without key word ‘‘HIV.’’
 Laboratory results: For qualitative tests, we classified the
tests into three groups by their results: positive tests were
indicated by key words ‘‘positive,’’ ‘‘present,’’ ‘‘reactive,’’ and ‘‘detected’’; negative tests were indicated by
key words ‘‘negative’’ and ‘‘nonreactive’’; while indeterminate tests were indicated by key words ‘‘indeterminate,’’ ‘‘comment,’’ and ‘‘pending.’’ For quantitative
tests, we kept tests with valid numeric results. We deleted tests for which results contained key words ‘‘cancel,’’ ‘‘not performed,’’ ‘‘not required,’’ and ‘‘N/A.’’
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